In a thought-provoking Q&A with BioPharma BoardRoom, Demaris Mills, President of Integrated DNA Technologies (IDT), discusses the transformative advanc...
In a detailed interview with BioPharma BoardRoom, Kerstin Pohl, Senior Global Marketing Manager for Gene Therapy & Nucleic Acid at SCIEX, delves into t...
As the biopharma industry continues to evolve, sustainability has emerged as a key driver of progress. Ryan Walker, Sustainability Program Leader at Cyt...
In an exclusive interview with BioPharma Boardroom, Dr. Mehmood Khan, Chief Executive Officer of Hevolution Foundation, shares insights into the tr...
Agilent Technologies Inc. (NYSE: A), a global leader in life sciences, diagnostics, and applied chemical markets, has released its financial results for ...
Net sales up organically by 3.8% to € 5.3 billion EBITDA pre up organically by 16.9% to € 1.6 billion EBITDA ...
Pfizer Inc. (NYSE: PFE) announced that after a comprehensive internal and external selection process, the company is appointing Chris Boshoff, M.D., PhD, a...
NEXGEL, Inc. (“NEXGEL” or the “Company”) (NASDAQ: “NXGL”), a leading provider of ultra-gentle, high-water-content hyd...
Reduces workforce by roughly 40%; expects annualized cost savings of more than $35 million Discontinues development of therapeutics division and commenc...
With a renewed focus on drug prices, fast-track approvals, and ‘America First’ production, industry experts warn pharma to brace for Tr...
Financial report for the period 1 January 2024 to 30 September 2024 &nb...
Illumina, Inc. shared its financial results for the third quarter of fiscal year 2024, demonstrating resilience amidst macroeconomic challenges and...
Reports record third quarter 2024 revenue of $7.6 million, representing growth of 24%compared to the third quarter of 2023 Placed seven Growth Direct&...
Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, reported its consolidated financial results for the third quarter...
© 2024 Biopharma Boardroom. All Rights Reserved.
